1. Home
  2. |Insights
  3. |What impact will the new Urban Wastewater Treatment Directive really have on the pharma and cosmetic industries?

What impact will the new Urban Wastewater Treatment Directive really have on the pharma and cosmetic industries?

Webinar | 12.05.24, 2:00 PM CET - 3:15 PM CET

Address

Virtual

December 5, 2024

View On Demand Here

What impact will the new Urban Wastewater Treatment Directive really have on the pharma and cosmetic industries?


Join us for an in-depth discussion led by industry experts and legal professionals as they demystify the complexities of the new Urban Wastewater Treatment Directive (UWWTD) and its impact on the pharmaceutical and cosmetic industries. This comprehensive webinar will cover:

  • The background and context of the New UWWTD
  • Impact assessments, scientific data and technical information regarding its adoption
  • The directive’s scope and core requirements
  • Likely impact on pharmaceutical and cosmetic products and supply chains
  • Concerns of a chilling effect on growth and competitiveness
  • Links to other EU and EEA law and policy aspects, including other EPR schemes
  • The Swiss experience: different approaches and different funding models


Discover key insights through this in-depth discussion led by industry experts and legal professionals on the new UWWTD. 

Speakers

  • Marcus Navin-Jones, Senior Counsel, Crowell & Moring Brussels
  • Ilona Kirhensteine, Associate Director - WSP
  • Bryan Regan, PSCI - Associate Director Environmental Governance - Novartis
  • Athina Giannoutsou, Associate Director of Public Affairs, EFPIA and The Inter-Association Task Force on Pharmaceuticals in the Environment (PiE)
  • Carmela Ciarliero, Public Affairs Manager, Cosmetics Europe

Participants

  • Luca Prosdocimo, Senior Manager International Trade and Public Affairs, Medicines for Europe 
  • Luis Rhodes Baiao PharmD, Governmental and Public Affairs Manager, AESGP

To learn more about this topic please read this article.

For more information, please visit these areas: Regulatory — Brussels Practice, Brussels Practice, Life Sciences — Brussels Practice, Environmental, Social, and Governance, Environment and Natural Resources, Sustainability and Environmental, Social, and Governance (ESG)

Participants

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

View All Insights